林奇综合征患者的肉瘤和对免疫治疗的反应
Michael S Shehata1, Serena Y Lofftus1, Joon Y Park1
1Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, California, USA.
Journal of surgical oncology
|December 28, 2023
概括
患有林奇综合征 (LS) 相关瘤的患者表现出较高的瘤突变负担和免疫透. 这些LS瘤对PD1阻断免疫疗法反应良好,这表明应该考虑这些患者.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 林奇综合征 (LS) 是一种遗传性疾病,由于DNA不匹配修复缺陷而增加癌症风险.
- 瘤通常与LS无关,但证据表明LS家族的发病率较高.
- 瘤通常具有较低的突变负担和较差的免疫反应,限制了免疫治疗的有效性.
相关概念视频
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K